Skip to main content
. 2019 Apr 12;294(15):5805–5806. doi: 10.1074/jbc.H119.008479

Figure 1.

Figure 1.

To overcome limitations in TCR engineering, the authors established new mammalian cell-based platforms for enhancing receptor affinity (left) and soluble production (center). These platforms generated TCRs that potently and specifically recognized APC-presented CMV antigens both in transduced T cells (right top) and as soluble TCR–antibody fusion proteins (right bottom).